TruBridge (TBRG) Proxy filing summary

Executive summary

• IKS Health will acquire 100% of TruBridge in an all-cash transaction valued at $26.25 per share, with an enterprise value of approximately $557 million.

• The transaction is expected to close in the third calendar quarter of 2026, pending customary closing conditions, including shareholder and regulatory approvals.

• TruBridge will be delisted from NASDAQ upon completion of the transaction.

• The combined entity will support over 2,000 healthcare organizations and 150,000 clinicians, enhancing service offerings across ambulatory and acute care.

• The merger aims to accelerate AI-driven innovation and create a scalable delivery model by integrating complementary platforms and expertise.

Voting matters and shareholder proposals

• Shareholder approval is required for the proposed acquisition, and a proxy statement will be filed and mailed to stockholders.

• Security holders are urged to read the proxy statement and related materials when available, as they will contain important information about the transaction.

Board of directors and corporate governance

• Directors and executive officers of TruBridge may be deemed participants in the proxy solicitation for the proposed transaction.

• Information about the board, governance, and executive compensation is available in prior proxy statements and SEC filings.